👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Moderna Stock Jumps After FDA Advisors Recommend Booster Shot

Published 10/14/2021, 04:11 PM
Updated 10/14/2021, 04:16 PM
©  Reuters
PFE
-
MRNA
-

By Sam Boughedda

Investing.com — On Thursday, an FDA advisory panel voted unanimously to give booster shots of Moderna 's (NASDAQ:MRNA)  Covid-19 vaccine to people aged 65 and older and other vulnerable citizens. 

The non-binding decision got 19 yes votes after a two-day meeting based on whether available data on Moderna's Covid-19 vaccine booster supports a booster at least six  months after being vaccinated.

The FDA’s Vaccines and Related Biological Products Advisory Committee has brought Moderna's booster shot in line with Pfizer (NYSE:PFE) and BioNTech’s vaccine, which was authorized for the same group less than a month ago.

As the approval has come from an advisory committee, the FDA doesn't have to follow its advice. However, it often does, and a final decision from the FDA could arrive in the next few days. A CDC advisory panel would then vote on the FDA's recommendation. 

Moderna's stock price jumped over 4% after news of the panel's approval. It closed Thursday's session at $331.88, climbing 3.23% from Wednesday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.